Research programme: topical phosphodiesterase 4 inhibitors - Amalyte Pharmaceuticals
Latest Information Update: 01 Apr 2011
At a glance
- Originator Amalyte Pharmaceuticals
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Research Atopic dermatitis; Psoriasis
Most Recent Events
- 01 Apr 2011 Early research is ongoing in USA